- recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children with Hypochondroplasia
This study looks at a new medicine called Voxzogo for children with hypochondroplasia, a condition affecting bone growth. Researchers want to see if Voxzogo helps children grow taller and if it's safe to use compared to a dummy medicine.
Spain · Germany · Italy - authorisedTherapeutic exploratory (Phase II)
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE
This study looks at a medicine called infigratinib for children with hypochondroplasia. It's an ongoing part of an earlier study, checking how safe the medicine is long-term and if it helps with growth and overall health.
Spain · Norway - recruiting
Prospective Longitudinal Multicentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia
This study is looking at how children and adults with achondroplasia or hypochondroplasia move their arms and legs. We want to see if a special digital tool called Syde® can accurately measure these movements. This will help us understand the conditions better.
Belgium · France · United Kingdom - enrolling by invitationPHASE2
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
This study looks at a medicine called Infigratinib for children aged 3 to 18 with a condition called Hypochondroplasia. It's an ongoing study to understand its long-term safety and how well it helps kids who have already been part of a previous study.
United States · Australia · Canada - enrolling by invitationPHASE3
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
This study looks at the long-term effects and safety of a medicine called vosoritide for children with hypochondroplasia, a condition that affects how bones grow. It's for children who have already been part of an earlier study.
United States · Australia · Canada - recruiting
Prospective Clinical Assessment Study in Children With Hypochondroplasia
This study looks at how hypochondroplasia (a type of short stature) affects children aged 2.5 to 16 years over time. Researchers want to understand their growth, health issues, daily life, and learning. No new medicines are given.
United States · Australia · Canada - active not recruitingPHASE3
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
This study is testing a new medicine, vosoritide, for children aged 3 to 17 with hypochondroplasia (a type of short stature). It will compare vosoritide to a dummy medicine (placebo) to see if it helps children grow taller over 52 weeks.
United States · Australia · Canada - recruitingPHASE2
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
This study is looking at a new medicine called vosoritide for very young children (under 3 years old) with hypochondroplasia. We want to see if it's safe and helps them grow better compared to a dummy medicine.
United States · Australia · France - recruiting
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
This study looks at how children with hypochondroplasia grow over time and how their condition changes. We'll collect information like their height and other details to better understand this rare genetic condition and improve care.
United States · Argentina · Australia - enrolling by invitationPHASE2, PHASE3
An Interventional Study of Infigratinib in Children With Hypochondroplasia
This study is looking at a new medicine called infigratinib for children with hypochondroplasia (a type of short stature). It's checking if the medicine is safe and helps children grow better. Children aged 3 to 18 might be able to take part.
United States · Australia · Canada